| Prev Close | 199.31 |
| Day Low/High | 200.36 / 205.46 |
| 52 Wk Low/High | 166.30 / 211.90 |
| Avg Volume | 2.98M |
Amgen Inc. (AMGN)
204.02
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 599.70M |
| Market Cap | 119.53B |
| EPS | 12.70 |
| P/E Ratio | 15.77 |
| Div & Yield | 5.80 (2.79%) |
Latest News
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
3 Autopilot Funds for a High-Yield Portfolio
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Amgen Charts Indicate Bounce Possible Within a Longer-Term Downtrend
In the short run the stock of this biotech giant could bounce as momentum has slowed, but the bigger picture is for further weakness.
Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Real Money Post-Industrial Average Leaves Major Indices in the Dust
RMPIA outperformed once gain during April.
Stalking an Entry in Pioneer Natural Resources Into Earnings
Plus a possible setup in Amgen as earnings approach.
Are These Stocks the Best of the Best?
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
The Real Money Post Industrial Average Continues to Soar
The RMPIA rose 10.5% during the first half of the current quarter.
Real Money Post-Industrial Average Shines in January, Outperforming S&P 500
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Apple Jumps After Reporting a Slight Earnings, Revenue Beat
Apple shares are up nearly 4% in after-hours trading.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon
Do we have to run for the hills? Not necessarily.
Amgen Is a Bright Spot in This Stock Market: Here's How to Play It
After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
The Real Money Post-Industrial Average Has Jumped 11% So Far This Year
For the month of November RMPIA climbed 1.2% month over month.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Amgen Is Showing Independent Strength in a Bullish Sign for the Future
Investors should continue to hold Amgen.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
